New JAK Inhibitors

Catalog No.	Product Name	Information
E6928	Fadeucravacitinib	Fadeucravacitinib (ICP-488) is an orally active, highly selective allosteric TYK2 inhibitor. Fadeucravacitinib specifically binds the TYK2 JH2 pseudokinase domain, thereby suppressing JH1 kinase activity and blocking IL-23, IL-12 and type I interferon signaling. Fadeucravacitinib can be used in research related to psoriasis and other autoimmune diseases.
E6417	Envudeucitinib (ESK001)	Envudeucitinib (ESK001) is an orally active and selective TYK2 allosteric inhibitor which blocks JH1 catalytic activity by specifically binding to the JH2 domain of TYK2, thereby inhibiting downstream signaling pathways. It exhibits the potential to be used in research on plaque psoriasis, systemic lupus erythematosus, and other immune-mediated diseases.
E1828	BHV-8000	BHV-8000 (TLL-041) is a first-in-class, oral, brain-penetrant, dual TYK2/JAK1 selective inhibitor that targets the JAK-STAT pathway signaling implicated in the mixed inflammatory response driving progression of many neuroinflammatory and neurodegenerative conditions, including Parkinson's disease, Alzheimer's disease, and multiple sclerosis.
S9814	BMS-986202	BMS‑986202 is a potent, selective and orally active inhibitor of TYK2 that binds to the TYK2 pseudokinase domain (JH2) with an IC50 of 0.19 nM and a Ki of 0.02 nM.
S3521	Golidocitinib(AZD4205)	Golidocitinib (AZD4205) (Compound 21) is a highly selective and potent inhibitor of Janus kinase 1 (JAK1), with an IC50 of 0.07 μM for JAK1 and much weaker inhibition of JAK2 (IC50 > 15 μM). It also exhibits potent antitumor effects in NSCLC xenograft models in preclinical studies.
≡ All JAK Inhibitors